WT1 and small cell lung carcinoma: In this study, using LK79 – a SCLC cell line – as a target, which produces high amounts of CCL2 (Table 2 and Fig. 1A), and effector CTLs double-transfected to express WT1-specific TCR and CCR2, we successfully demonstrated both the feasibility and advantages of targeting an optimal chemokine produced by tumor cells, to achieve successful adoptive therapy.